Roche Forecasts 2026 Growth, Cites Drug-Pipeline Strength

Date:




The Swiss drugmaker expects sales and core earnings per share to grow at constant currencies this year, partly due to the strength of its drug pipeline.



Source link

Share post:

Subscribe

spot_imgspot_img

Popular

More like this
Related